Sophiris Bio(加拿大)

Sophiris Bio

加拿大SophirisBiowww.sophirisbio.comProtoxTherapeuticsInc.(溫哥華，Vancouver)宣布公司就PRX302藥物項(xiàng)目己向美國FDA提出攝護(hù)腺癌治療藥物的研究中新藥申請(qǐng)(investigationalnewdrug，IND)。一旦在FDA的IND案通過，公司預(yù)期便可以在下一年進(jìn)行復(fù)發(fā)型部位固定攝護(hù)腺癌臨床期測試。2012年加拿大ProtoxThe rapeuticsInc改名為SophirisBio ProtoxTherapeuticsusesgeneticengineeringtotransformnaturallyoccurringproteinsintonoveltargetedtherapeuticsforthetreatmentofprostatediseasesandvariouscancers.Protoxisadvancingapipelineofclinical-stageproductcandidatesderivedfromitsPORxin™andINxin™technologyplatforms.Protox’sleaddrugscurrentlyinclinicaldevelopmentincludePRX302forthetreatmentofbenignprostatichyperplasia(BPH,commonlyknownasenlargedprostate)andlocalizedprostatecancer,aswellasPRX321forprimarybraincancer(glioblastomamultiformeandastrocytoma).